DSS, Inc. Announces Launch of Proposed Public Offering
Rhea-AI Summary
DSS (NYSE: DSS) announced a proposed public offering of its common stock to be sold by the company, with net proceeds intended for general corporate and working capital purposes. The offering is subject to market conditions and may not be completed on a specific timeline or at specific terms.
Aegis Capital Corp. is sole book-running manager on a firm commitment basis. The offering will be made under an effective shelf registration statement (Form S-3 No. 333-281974, declared effective Nov 5, 2024), and a final prospectus supplement and accompanying prospectus will be filed with the SEC.
Positive
- Access to cash for general corporate and working capital needs
- Sole book-runner secured: Aegis Capital Corp. on firm commitment
- Offering covered by effective Form S-3 shelf registration
Negative
- Potential shareholder dilution from issuance of new common stock
- Completion, size, and terms are uncertain and market-dependent
- No specified proceeds amount or timetable disclosed
Market Reality Check
Peers on Argus
While DSS was up 17.8% before the offering news, sector peers in packaging/containers showed mixed moves, with several names in momentum scanners moving down (sector median about -6.0%). This points to company-specific dynamics rather than a broad sector move.
Market Pulse Summary
This announcement details a primary public offering of DSS common stock, with proceeds earmarked for general corporate and working capital needs. The deal is underwritten on a firm commitment basis and relies on an effective Form S-3 registration, with final terms to be set in a prospectus supplement. Investors may focus on pricing, discount, and final size, along with existing balance sheet pressures highlighted in recent SEC filings, when evaluating impact.
Key Terms
public offering financial
common stock financial
book-running manager financial
firm commitment basis financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
prospectus regulatory
AI-generated analysis. Not financial advice.
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE: DSS) (the “Company”), a multinational company operating across diverse industries including packaging, wealth management, and biohealth innovation, today announced that it has commenced a public offering to offer and sell shares of its Common Stock.
All of the shares of Common Stock are being offered by the Company (the “Offering”).
The Company intends to use the net proceeds from the Offering for general corporate and working capital needs. The Company’s Common Stock is trading on the NYSE American LLC under the symbol “DSS”. The Offering is subject to market conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.
Aegis Capital Corp. is acting as the sole book-running manager for the offering on a firm commitment basis.
The offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-281974) previously filed with the U.S. Securities and Exchange Commission (SEC) on October 31, 2024, and declared effective by the SEC on November 5, 2024. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About DSS, Inc.
DSS, Inc. is a multinational company operating across multiple business lines including health and wellness, packaging, real estate, and securities and blockchain. The Company operates a business model based on developing high-growth subsidiaries and unlocking value through strategic IPOs and public listings. For more information, visit www.dssworld.com.
Forward-Looking Statements
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
For investor and media inquiries or additional information, please contact:
Investor Contact:
DSS, Inc.
Investor Relations
ir@dssworld.com
+1 (585) 565-2422